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Abstract
Background: Neonatal manifestation of life-threatening hyperammonemic encephalopathy in urea cycle disorders
(UCD) is often misdiagnosed as neonatal sepsis, resulting in significantly delayed start of specific treatment and
poor outcome. The major aim of this study was to identify specific initial symptoms or signs to clinically distinguish
hyperammonemic encephalopathy in neonates from neonatal sepsis in order to identify affected individuals with
UCD and to start metabolic therapy without delay. Furthermore, we evaluated the impact of diagnostic delay, peak
plasma ammonium (NH4
+) concentration, mode of emergency treatment and transfer to a tertiary referral center on
the outcome.
Methods: Detailed information of 17 patients (born between 1994 and 2012) with confirmed diagnosis of UCD and
neonatal hyperammonemic encephalopathy were collected from the original medical records.
Results: The initially suspected diagnosis was neonatal sepsis in all patients, but was not confirmed in any of them.
Unlike neonatal sepsis and not previously reported blood pressure increased above the 95th percentile in 13 (81%)
of UCD patients before emergency treatment was started. Respiratory alkalosis was found in 11 (65%) of UCD
patients, and in 14 (81%) plasma NH4
+concentrations further increased despite initiation of metabolic therapy.
Conclusion: Detection of high blood pressure could be a valuable parameter for distinguishing neonatal sepsis
from neonatal manifestation of UCD. Since high blood pressure is not typical for neonatal sepsis, other reasons
such as encephalopathy and especially hyperammonemic encephalopathy (caused by e.g. UCD) should be
searched for immediately. However, our result that the majority of newborns with UCD initially present with high
blood pressure has to be evaluated in larger patient cohorts.
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Background
The physiologic function of the urea cycle is the irrevers-
ible fixation of ammonium (NH4
+) to form water-soluble
urea and thus to clear excess nitrogen produced by pro-
tein catabolism. Deficiency in one of the six enzymes or
two transporters of the urea cycle impairs ureagenesis.
The majority of these diseases results in hyperammonemia
leading to rapidly progressing encephalopathy with severe
neurologic sequelae or even death. Patients with the most
severe neonatal manifestation present with first symptoms
after a short symptom-free interval ranging from a few
hours to days, while individuals with attenuated late dis-
ease onset may present at any age after the newborn
period. The overall prevalence of urea cycle disorders
(UCD) has been estimated to be approximately 1 in
35,000 for the United States [1] and 1 in 52,000 live births
in Germany, Austria and Switzerland [2]. At least half of
them present during the newborn period.
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Newborns with UCD initially present with nonspe-
cific symptoms such as vomiting, feeding refusal, irrit-
ability, lethargy, respiratory problems and seizures [3–
5]. Further progress leads to apnea, cerebral edema
and death. Emergency care, stabilization of the neo-
nate during acute illness and immediate start of
NH4
+detoxification are indispensable for survival and
for the prevention of irreversible brain damage. The
clinical phenotype is often mistaken as neonatal sep-
sis. Since hyperammonemic encephalopathy of UCD
patients shares clinical overlap with other diseases be-
coming manifest in the newborn period, particularly
neonatal sepsis, and hence cannot be reliably identi-
fied clinically, diagnosis and start of specific emer-
gency therapy is often delayed.
The aim of this study was to identify clinical pa-
rameters that help to distinguish between hyperam-
monemic encephalopathy and neonatal sepsis and
reduce diagnostic and therapeutic delay. Furthermore,
we evaluated the impact of diagnostic delay, peak
plasma ammonium (NH4
+) concentration, mode of
emergency treatment and transfer to a tertiary referral
center on the outcome.
Methods
Seventeen patients, born between 1994 and 2012, with
confirmed inherited deficiency of argininosuccinate lyase
(ASL; MIM #207900), argininosuccinate synthetase 1
(ASS1; MIM #215700), carbamylphosphate synthetase 1
(CPS1; MIM #237300) or ornithine transcarbamylase
(OTC; MIM #311250) and neonatal hyperammonemic
encephalopathy were included. Sixteen of them were
transferred to our center for emergency treatment. In-
formation on pregnancy and delivery, onset of symp-
toms, diagnostic investigations, treatment protocols and
outcome were collected from the original medical re-
cords of the transferring hospitals and our center.
IBM SPSS 20 for Windows (SPSS INC., Chicago, IL,
USA) was used for statistical analyses. Unless stated
otherwise, continuous variables are presented as mean ±
standard deviation (SD) and range. The reference values
for the age-appropriated 95th percentile of systolic, dia-
stolic and mean arterial blood pressure (MAD) in new-
borns in the first days of life were based on the values
collected by Kent et al. [6, 7]. Differences between
groups were tested by Student’s t test or, if normality
failed, with Kruskal–Wallis or Mann-Whitney U
rank-sum test. P values < 0.05 were regarded as statisti-
cally significant in a explorative sense.
The study was performed in accordance with the Dec-
laration of Helsinki of 1975, as revised in 2013 after ap-
proval by the ethics committee of the University of
Heidelberg, Germany (S-416/2011).
Results
Study population
Two patients (one female, one male) with CPS1 deficiency,
six (all male) with OTC deficiency, seven (three female, four
male) with ASS1 deficiency and two (one female, one male)
with ASL deficiency were included in this study. All pa-
tients except patient #15 (ASS1 deficiency), who was identi-
fied by newborn screening, were diagnosed after the
manifestation of symptoms during the newborn period.
Obstetric history and birth
All patients were term newborns, except for patient #6
who was delivered at a gestational age of 36 weeks. Mean
gestational age was 39 weeks (SD = 1.5 weeks; range 36 to
41 weeks) and the mean birth weight was 3240 g (SD =
397 g; range 2685 g to 4075 g). Mean APGAR scores were
8.7 (SD = 0.8) at 1min, 9.9 at 5 (SD = 0.3) and at 10min
(SD = 0.2). Patients were born by vaginal delivery (n = 12)
or caesarian section (n = 5; one primary and four second-
ary cesarean section).
Clinical presentation and diagnosis
Table 1 summarizes initial signs and symptoms of the 17
patients. Mean onset of symptoms was at the 4th day of
life (SD = 1.7 days; range 2–9 days). Affected newborns
most commonly presented with respiratory distress,
muscular hypotonia, and lethargy. Seizures were recog-
nized in one patient before admittance. Interestingly, 13
of 16 patients (81%) presented with increased blood
pressure above the 95th percentile before the start of
emergency treatment, most of them being lethargic and
severely compromised (Fig. 1). Mean systolic, diastolic
and MAD pressure was 95mmHg, 62.5 mmHg, 76
mmHg (SD = 15.3, 13.7, 13.1; range 71–121 mmHg, 50–
88mmHg, 58–98mmHg). Of note, none of the patients
received additional intravenous fluid applications includ-
ing antibiotic therapy before blood pressure measure-
ments. In the 3 newborns with initial normal blood
pressure values, the blood pressure remained at the level
and did not increase secondary. Even 3 h after admission
to the transferring hospital, 9 of the 13 children with ele-
vated initial blood pressure continued to have elevated
blood pressure. Of the remaining four, no blood pressure
was documented in three patients at that time and one
newborn (#1) was already intubated. Mean systolic, dia-
stolic and MAD pressure was 100 mmHg, 71 mmHg, 86
mmHg (SD = 8.15, 12.7, 10.9; range 89–111 mmHg, 60–
94mmHg, 70–98mmHg), respectively. Most children
experienced a drop in blood pressure with intubation
and associated sedation. Looking at the blood pressure
in the individual disease groups, an increase from CPS1
via OTC, ASS to ASL was observed for systolic, diastolic
and MAD pressure (Table 2). However, there was no sig-
nificant difference between systolic (p = 0.4) and MAD
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Table 1 Initial clinical presentation and metabolic derangement of neonatal UCD patients
Initial blood gases Symptoms# NH4
+
No Sex Deficiency
of
pH Base
excess
Lactate CO2 SBP DBP MAD Onset At
obstetric unit
On
admission
at NICU
First
test result
On
admission
at NICU
Peak
NH4
+
Time until
NH4
+ <
150 μmol/l
mmol/l mmHg Day of life (μmol/l) hours
1° F CPS1 7.42 −2.3 6.0 76.7 86 52 69 3 7 1, 3, 6 4000 4420 4420 35
2 M CPS1 7.36 −9.1 5.7 26.1 74 50 58 3 n.d. 1, 4 673 835 1100 21
3° M OTC 7.52 2.9 2.6 29.6 84 53 63 9 4, 8 1, 4, 8 385 136 385 9
4° M OTC 7.47 −1.5 4.0 30.0 109 61 72 5 2, 4 2, 4 240 676 676 28
5 M OTC 7.46 −2.4 5.2 26.0 71 56 81 2 4 1, 4 286 3363 4050 28
6 M OTC 7.17 −4.1 3.9 n.d. 80 55 63 3 4, 5, 9 1, 4, 6, 1000 1951 2213 30
7° M OTC 7.36 1.4 2.5 50.5 110 84 98 4 1 1, 3 1494 3516 3516 34
8 M OTC 7.48 −4.1 2.9 21.5 n.d. n.d. n.d. 3 1 1, 6 750 1750 1750 34
9° M ASS1 7.55 0 3.7 25.8 121 83 94 4 1, 2 1, 4 1078 590 1078 12
10° F ASS1 7.39 −3.8 7.2 33.2 95 64 74 3 1 1, 3 232 1430 1430 35
11° M ASS1 7.55 −5.5 5.2 19.7 95 65 78 4 2,4 1, 4 735 1104 1104 14
12° F ASS1 7.55 −2.3 4.9 20.4 111 70 91 4 2, 4, 5 1, 4, 6 484 1091 1091 33
13° M ASS1 7.48 −3.4 2.7 24.3 92 61 71 3 1, 6 1, 6 235 1376 1645 24
14° F ASS1 7.45 0.4 3.5 34.7 110 88 95 4 1 1 1399 1734 >
2000
15
15*†° M ASS1 7.34 −7.6 5.9 32.0 85 61 71 7 −/−* 4 402 n.d. 402 4
16° F ASL 7.36 −4.9 5.8 35.0 110 84 89 3 1, 2, 3 1, 3, 6 1256 1082 1256 24
17° M ASL 7.52 2.4 n.d. 29.5 108 88 94 6 1, 2, 4 1, 3, 5 1065 1100 1100 41
ASL, Argininosuccinate lyase; ASS1, Argininosuccinate synthetase 1; CPS1, Carbamylphosphate synthetase 1; CO2, Carbon dioxide; DBP, Diastolic blood
pressure; F, Female; M, Male; NH4
+, Plasma ammonium concentration; No, Number; MAD, Mean arterial pressure; NICU, Neonatal intensive care unit; SBP,
Systolic blood pressure; OTC, Ornithine transcarbamylase deficiency;
#Symptoms: 1: respiratory distress, 2: poor feeding, feeding difficulties, 3: muscular hypertonia, 4: lethargy/ muscular hypotonia, 5: hypothermia, 6:
acrocyanosis, 7: seizures, 8: vomiting, 9: hypoglycemia
° = blood pressure above the 95th percentile * = identified by newborn screening, †= not transferred to our centre; n.d. = not documented,
Fig. 1 Initial systolic, diastolic and mean arterial blood pressure of the newborns with the respective 95th percentile. Legend: ▲systolic blood
pressure; ■ mean aterial blood pressure; ● diastolic blood pressure
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pressure (p = 0.21) for each individual disease. Only with
diastolic pressure a significance (p = 0.038) was detected
between CPS1 and ASL. In one patient, initial blood
pressure was not reported. In all patients, neonatal sep-
sis was initially suspected, but was not confirmed in any.
With the exception of patient (#1), who was immediately
intubated in the referring clinic, none of the newborns
initially received a volume bolus.
In the initial work-up, all patients received cranial
ultrasound, 14 of them echocardiography and eight ab-
dominal ultrasound. Thorathic X-rays were performed
in 13 patients, while eight patients received a lumbar
puncture during the work-up of neonatal sepsis. Twelve
received intubation and mechanical ventilation due to
respiratory distress. One newborn (#1) was intubated
immediately after admission to the transferring hospital.
The other eleven were intubated before the transfer to
our center. Two patients required catecholamines after
intubation and eight of them a central venous catheter.
Laboratory tests focusing on parameters of neonatal
sepsis (blood count and c-reactive protein (CRP)) were
obtained within two hours. Twelve patients received an-
tibiotics immediately after initial blood samples were
taken at the transferring pediatric hospital. The anti-
biotic therapy varied according to the individual stand-
ard procedures. Six newborns received antibiotic triple
therapy with ampicillin, cephalosporin plus an aminogly-
coside. Three newborns obtained ampicillin and amino-
glycoside, one received ampicillin plus cephalosporine,
one got cephalosporine and glycopeptides and one
received only cephalosporine. Blood gases (Table 1) were
determined in all patients showing means for pH of 7.46
(SD = 0.1; range 7.17–7.55), base excess (BE) -2.4 (SD =
3.2; range − 9.1 - 2.9) and carbon dioxide (CO2) of 29.6
mmHg (SD = 13.6 mmHg; range 19.7–76.7 mmHg). In
our population, respiratory alkalosis at initial presenta-
tion was present in 11 patients (65%). One patient (#1)
with respiratory insufficiency and thus elevated CO2
(76.7 mmHg) was intubated immediately after admit-
tance to the referring hospital. Plasma NH4
+ concentra-
tions were determined with a mean delay of 3 h after
admission to a Pediatric Department (SD = 11.5 h; range
1–41 h; except for #15 who was identified by newborn
screening). Mean initial NH4
+ concentration was
735 μmol/l (SD = 897 μmol/l, range 232–4000 μmol/l). In
all patients first therapeutic measures following suspi-
cion of a UCD were transient stop of protein intake and
intravenous application of glucose (15–20 g/kg/d, with
or without insulin). Two patients (# 1 and #2) received
no additional metabolic therapy until in-patient admis-
sion in our center. Five patients received intravenous ap-
plication of only arginine hydrochloride (#7, #8, #10,
#14, #18), one patient (#11) only intravenous sodium
benzoate and nine patients both medications. Eight pa-
tients received L-carnitine.
Progress after transferal
Overall 16 UCD patients (except #15) from 14 different
hospitals were transferred to the neonatal intensive care
unit (NICU) of our center after a mean time interval of
1.1 days (SD = 1.1 days; range 0–4 days) following the start
of symptoms. Although emergency therapy was started in
the referring hospitals, mean plasma NH4
+ concentrations
further increased from 735 μmol/l (SD = 897 μmol/l; range
232–4000 μmol/l) to 1240 μmol/l (SD = 1171 μmol/l;
range 136–4420 μmol/l) at arrival in our center and three
patients required immediate intubation and mechanic
ventilation due to respiratory insufficiency. Although
intravenous emergency treatment with high glucose,
arginine hydrochloride and sodium benzoate was intensi-
fied, plasma NH4
+ concentrations increased further in five
patients before extracorporeal detoxification was started.
Mean maximum NH4
+ concentration was 1537 μmol/l
(SD = 1238 μmol/l; range 385–4420 μmol/l). Looking at
NH4
+ concentrations in the individual disease groups
there was no significant difference between mean initial
NH4
+ concentrations (p = 0.68) and on admittance at
NICU (p = 0.74) (Table 2).
Extracorporeal detoxification with hemodialysis/hemo-
filtration via central venous Shaldon catheter was per-
formed in 15 UCD patients. Mean time interval between
admission to our center and start of hemodialysis/hemo-
filtration was 3.3 h (SD = 1.4 h, range 0.4–5.5. h). A mean
duration of 24.8 h (SD 10.4 h, range 4–41 h) was
Table 2 Mean blood pressure, mean initial ammonium level in transferring hospital and at admittance to NICU subdivided by UCD
enzyme deficiency
Deficiency of Blood pressure (mmHg) NH4
+ (μmol/l)
SBP DBP MAD First test result On Admission at NICU
CPS1 80 51 64 2376 2628
OTC 84 56 72 568 1851
ASS1 95 65 78 484 1240
ASL 109 86 92 1160 1091
ASL, Argininosuccinate lyase; ASS1, Argininosuccinate synthetase 1; CPS1, Carbamylphosphate synthetase 1; DBP, Diastolic blood pressure; NH4
+, Plasma
ammonium concentration; No, Number; MAD, Mean arterial pressure; NICU, Neonatal intensive care unit; SBP, Systolic blood pressure; OTC, Ornithine
transcarbamylase deficiency;
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required to reduce plasma NH4
+ concentrations to
below 150 μmol/l. Hemodialysis/hemofiltration was con-
tinued for a mean of 23.5 h (SD = 14.8 h; range 1.5–52
h). In six patients, plasma NH4
+ concentrations in-
creased again after discontinuation of extracorporeal de-
toxification. In one patient, hemodialysis/hemofiltration
had to be started a second time.
Hypothermia was started in five patients. In analogy to
standard protocols for hypothermia treatment in asphyxi-
ated newborns, patients were cooled to 33.5 °C for 72 h
using Hico Variotherm 550 (Hirtz). No severe side effects
like coagulopathy were observed during hypothermia.
After 72 h body temperature was increased by 0.5 °C per
hour until a body temperature of 37 °C was reached.
During NICU management three patients required re-
suscitation. Two patients developed a hypovolemic
shock, one (#14) after bleeding from the umbilical vein
five days after insertion of the Shaldon catheter, and one
(#16) due to high fluid removal during hemodialysis. In
the course of resuscitation the latter patient developed a
pneumothorax. The third patient (#1) had cardiac arrest
following an episode of supraventricular tachycardia.
In patients #5, 7 and 8, therapy was discontinued in
the next days to come in agreement with their parents
due to an extremely low protein tolerance which was
much below minimal requirements for dietary treat-
ment. All of them had severe brain damage which was
also confirmed by MRI. They died 7.1 h (mean; SD = 7.1;
range 2.25–16.5) after discontinuation of intensive care
and metabolic therapy.
Eleven of the surviving patients have been regularly
followed by our outpatient clinic until now (mean age:
12 years, SD =5.1 years; range 2.4–19.9). Apart from #3
and #9 all showed impairments of intellectual and motor
functions. Both have in common that there was no fur-
ther increase until the admission in our center, but even
a halving of the initial NH4
+ concentration. But all other
values such as the time of the first NH4
+ concentration,
metabolic emergency therapy, need for ventilation or
dialysis differ.
Discussion
Hyperammonemic encephalopathy in newborns with
UCDs is a life-threatening metabolic emergency that re-
quires immediate and targeted treatment to prevent ir-
reversible brain damage and death. The diagnosis of
UCDs is often delayed, since clinical presentation
shows broad overlap with other neonatal emergencies,
in particular neonatal sepsis. The major aim of this
study is to better distinguish neonatal onset of UCDs
from the more frequent neonatal sepsis. The clinical
presentation of UCD patients in this study is in line
with previous reports on neonatal onset of UCD pa-
tients [3–5]: Progressive respiratory distress, muscular
hypotonia and lethargy were the most frequent clinical
symptoms. Striking and not previously reported was
the finding of high blood pressure during hyperammo-
nemic encephalopathy, a finding clearly distinguishing
between UCDs and neonatal sepsis. Blood pressure was
determined by oscillometry. Even in pediatric popula-
tion oscillometric and radial artery blood pressure are
closely correlated with only a small error [8]. In con-
trast to preterm infants there is no correlation between
blood pressure and birth weight, length or gestational
age in term infants [6, 7, 9]. In our cohort except one
all were term infants. As described above 13 out of 16
patients (81%) in our study had a blood pressure above
the age-appropriate 95th percentile [6] at first contact
with a pediatrician due to clinical worsening, with most
neonates being lethargic and severely compromised.
Therefore high blood pressure was not due to increased
activity or additional fluid administration. Beside activ-
ity an alternative cause of neonatal hypertension is in-
creased intracranial pressure due to cerebral edema
[10]. The initial cranial ultrasound including Doppler
and Power color Doppler examination, however,
showed no evidence for an apparent brain edema on
admittance. Alternatively, low plasma arginine concen-
trations, which are characteristic for urea cycle disor-
ders, can also be a reason for arterial hypertension.
Production of arginine is important for endogenous cel-
lular production of nitric oxide (NO), a potent vasodila-
tor [11]. Patients with UCD, except those with arginase
1 deficiency, have low arginine levels. In ASL deficiency
impaired systemic NO production is thought to rely on
disturbed formation of a complex including ASL and
endothelial NO synthase among other components
[12]. In a newborn receiving arginine for evaluation of
pituitary function a drop of blood pressure was seen
after infusion of arginine followed by re-rising after dis-
continuation [13]. Nelin et al. [14] showed that arginine
infusion lowers blood pressure in normotensive infants.
A few cases reported about children with ASL defi-
ciency and arterial hypertension. Arterial hypertension
was resolved with intravenous infusion of arginine [13,
15]. We aimed to test this hypothesis in our study
population, however, plasma arginine concentrations
were determined only in 5 of the 17 patients before
starting metabolic emergency treatment which also in-
cludes arginine. In addition, we were able to show that
the initial high blood pressure is not a one-off event,
but initially persisted in newborns with UCD. For most
of them, sedation and intubation led to a drop in blood
pressure. Since in neonatal sepsis and other causes of
severe disease systemic blood pressure is mostly re-
duced [16], elevated blood pressure, probably readily
explained by the pathophysiology of UCD, may be an
important indicator for UCD.
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Blood gases are often the first quantitative data avail-
able in a very sick infant. Since respiratory alkalosis was
present in 65% of patients at initial presentation, this
finding should be considered as another indicator of
UCDs in any rapidly deteriorating neonate [5, 17].
Three out of the 17 patients died in the course of their
first crisis. All others stayed alive, and 11 patients are
still followed regularly in our outpatient clinics (mean
follow-up time 13.6 years, SD = 5.5 years). Only two of
the 11 surviving patients (#3: peak plasma NH4
+ concen-
trations: 590 μmol/l and #9: 385 μmol/l) are not cogni-
tively disabled. Their favorable neurological outcome
may be due to only moderate peak plasma NH4
+ con-
centrations during the neonatal crisis. In addition to age
at disease onset the initial peak plasma NH4
+ concentra-
tion is an important predictor of the neurological out-
come [18, 19]. In a cohort of 456 patients, Posset et al.
[18] described an initial peak NH4
+above 500 μmol/l to
be associated with neurological impairment. In 88 pa-
tients with UCDs reported by Bachmann et al. [19] none
of the patients with an initial NH4
+ level above
300 μmol/l (first test result) or 480 μmol/l (peak)
achieved a normal neurological outcome. This has been
confirmed by other studies [20, 21]. In our population
we noticed no significant differences of plasma NH4
+
concentrations between specific UCDs, whereby number
of patients was small. Early diagnosis and immediate
start of metabolic therapy aiming to normalize plasma
NH4
+concentrations is the prerequisite to prevent irre-
versible brain damage [22]. Noteworthy, until extracor-
poreal detoxification was started, plasma NH4
+
concentrations further increased in the majority of pa-
tients despite intensified intravenous therapy with so-
dium benzoate, arginine and high-dose glucose therapy
in combination with insulin. This highlights that intra-
venous emergency treatment is often insufficient to
lower plasma NH4
+ concentrations rapidly and reliably
and therefore hemodialysis has to be considered early.
From this it can be concluded that a timely transport of
every patient with hyperammonemic encephalopathy to
a metabolic center which operates hemodialysis in neo-
nates should be considered, planned and organized.
Five patients were treated with hypothermia in
addition to pharmacologic and extracorporeal detoxifica-
tion. This potentially neuroprotective intervention has
been described in animal experiments and small clinical
trials in hepatic encephalopathy. One of the protective
effects of hypothermia may be the prevention of osmo-
lyte depletion in the brain. In astrocytes, NH4
+is revers-
ibly fixed to glutamate forming. The NH4
+/glutamine/
brain swelling hypothesis of hepatic encephalopathy sug-
gests that accumulation of glutamine causes astrocytes
to swell [23]. Decreased NH4
+ delivery to the brain when
patients with acute liver failure were cooled was referred
to by Jalan [24, 25]. Polderman [26] reported a reduction
of the metabolic rate by 8% per degree Celsius. There is
one study reporting first results about feasibility of
therapeutic hypothermia in neonatal hyperammonemia
due to UCD [27].
Conclusion
Unfortunately the diagnosis of UCDs is often delayed
[28]. Therefore it is most important to further increase
the awareness for UCDs as a differential diagnosis in
acutely ill neonates. Until now respiratory alkalosis had
been recognized as an easily detectable, but inconsistent
initial finding of UCDs [29]. Our study confirms this
previous observation and highlights for the first time
that elevated blood pressure might be an even better in-
dicator of UCDs in newborns and distinguishes it from
more frequent neonatal sepsis. Blood gases, blood pres-
sure and plasma NH4
+ should be determined without
delay in every sick neonate with suspected neonatal
sepsis.
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